Your browser doesn't support javascript.
Characterization of a new SARS-CoV-2 variant that emerged in Brazil.
Imai, Masaki; Halfmann, Peter J; Yamayoshi, Seiya; Iwatsuki-Horimoto, Kiyoko; Chiba, Shiho; Watanabe, Tokiko; Nakajima, Noriko; Ito, Mutsumi; Kuroda, Makoto; Kiso, Maki; Maemura, Tadashi; Takahashi, Kenta; Loeber, Samantha; Hatta, Masato; Koga, Michiko; Nagai, Hiroyuki; Yamamoto, Shinya; Saito, Makoto; Adachi, Eisuke; Akasaka, Osamu; Nakamura, Morio; Nakachi, Ichiro; Ogura, Takayuki; Baba, Rie; Fujita, Kensuke; Ochi, Junichi; Mitamura, Keiko; Kato, Hideaki; Nakajima, Hideaki; Yagi, Kazuma; Hattori, Shin-Ichiro; Maeda, Kenji; Suzuki, Tetsuya; Miyazato, Yusuke; Valdez, Riccardo; Gherasim, Carmen; Furusawa, Yuri; Okuda, Moe; Ujie, Michiko; Lopes, Tiago J S; Yasuhara, Atsuhiro; Ueki, Hiroshi; Sakai-Tagawa, Yuko; Eisfeld, Amie J; Baczenas, John J; Baker, David A; O'Connor, Shelby L; O'Connor, David H; Fukushi, Shuetsu; Fujimoto, Tsuguto.
  • Imai M; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Halfmann PJ; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711.
  • Yamayoshi S; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Iwatsuki-Horimoto K; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Chiba S; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711.
  • Watanabe T; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Nakajima N; Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.
  • Ito M; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kuroda M; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Kiso M; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711.
  • Maemura T; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Takahashi K; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Loeber S; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711.
  • Hatta M; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Koga M; Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706.
  • Nagai H; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711.
  • Yamamoto S; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Saito M; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Adachi E; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Akasaka O; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Nakamura M; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Nakachi I; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Ogura T; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Baba R; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Fujita K; Emergency Medical Center, Fujisawa City Hospital, Kanagawa 251-8550, Japan.
  • Ochi J; Department of Pulmonary Medicine, Tokyo Saiseikai Central Hospital, Tokyo 108-0073, Japan.
  • Mitamura K; Pulmonary Division, Department of Internal Medicine, Saiseikai Utsunomiya Hospital, Tochigi 321-0974, Japan.
  • Kato H; Department of Emergency & Intensive Care, Saiseikai Utsunomiya Hospital, Tochigi 321-0974, Japan.
  • Nakajima H; Pulmonary Division, Department of Internal Medicine, Saiseikai Utsunomiya Hospital, Tochigi 321-0974, Japan.
  • Yagi K; Department of Emergency & Intensive Care, Saiseikai Utsunomiya Hospital, Tochigi 321-0974, Japan.
  • Hattori SI; Department of Respiratory Medicine, Eiju General Hospital, Tokyo 110-8645, Japan.
  • Maeda K; Division of Infection Control, Eiju General Hospital, Tokyo 110-8645, Japan.
  • Suzuki T; Infection Prevention and Control Department, Yokohama City University Hospital, Kanagawa 236-0004, Japan.
  • Miyazato Y; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Kanagawa 236-0004, Japan.
  • Valdez R; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Kanagawa 236-0004, Japan.
  • Gherasim C; Department of Pulmonary Medicine, Keiyu Hospital, Kanagawa 220-8521, Japan.
  • Furusawa Y; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan.
  • Okuda M; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan.
  • Ujie M; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo 162-8655, Japan.
  • Lopes TJS; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo 162-8655, Japan.
  • Yasuhara A; Department of Pathology, University of Michigan, Ann Arbor, MI 48109.
  • Ueki H; Department of Pathology, University of Michigan, Ann Arbor, MI 48109.
  • Sakai-Tagawa Y; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Eisfeld AJ; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Baczenas JJ; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Baker DA; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • O'Connor SL; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711.
  • O'Connor DH; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Fukushi S; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Fujimoto T; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Proc Natl Acad Sci U S A ; 118(27)2021 07 06.
Article in English | MEDLINE | ID: covidwho-1276013
Semantic information from SemMedBD (by NLM)
1. Vitronecti PART_OF C5203676
Subject
Vitronecti
Predicate
PART_OF
Object
C5203676
2. Vitronecti ASSOCIATED_WITH C0042769
Subject
Vitronecti
Predicate
ASSOCIATED_WITH
Object
C0042769
3. Antigens AUGMENTS Immune response
Subject
Antigens
Predicate
AUGMENTS
Object
Immune response
4. Patients LOCATION_OF Plasma
Subject
Patients
Predicate
LOCATION_OF
Object
Plasma
5. Infected PROCESS_OF Patients
Subject
Infected
Predicate
PROCESS_OF
Object
Patients
6. Patients LOCATION_OF Serum
Subject
Patients
Predicate
LOCATION_OF
Object
Serum
7. Antibodie CAUSES C0042774
Subject
Antibodie
Predicate
CAUSES
Object
C0042774
8. Vitronectin, human PART_OF 2019 novel coronavirus
Subject
Vitronectin, human
Predicate
PART_OF
Object
2019 novel coronavirus
9. Vitronectin, human ASSOCIATED_WITH Virus Diseases
Subject
Vitronectin, human
Predicate
ASSOCIATED_WITH
Object
Virus Diseases
10. Antigens AUGMENTS Immune response
Subject
Antigens
Predicate
AUGMENTS
Object
Immune response
11. Patients LOCATION_OF Plasma
Subject
Patients
Predicate
LOCATION_OF
Object
Plasma
12. Infected PROCESS_OF Patients
Subject
Infected
Predicate
PROCESS_OF
Object
Patients
13. Patients LOCATION_OF Serum
Subject
Patients
Predicate
LOCATION_OF
Object
Serum
14. Antibodies, Neutralizing CAUSES Virus Replication
Subject
Antibodies, Neutralizing
Predicate
CAUSES
Object
Virus Replication
ABSTRACT
The spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays a key role in viral infectivity. It is also the major antigen stimulating the host's protective immune response, specifically, the production of neutralizing antibodies. Recently, a new variant of SARS-CoV-2 possessing multiple mutations in the S protein, designated P.1, emerged in Brazil. Here, we characterized a P.1 variant isolated in Japan by using Syrian hamsters, a well-established small animal model for the study of SARS-CoV-2 disease (COVID-19). In hamsters, the variant showed replicative abilities and pathogenicity similar to those of early and contemporary strains (i.e., SARS-CoV-2 bearing aspartic acid [D] or glycine [G] at position 614 of the S protein). Sera and/or plasma from convalescent patients and BNT162b2 messenger RNA vaccinees showed comparable neutralization titers across the P.1 variant, S-614D, and S-614G strains. In contrast, the S-614D and S-614G strains were less well recognized than the P.1 variant by serum from a P.1-infected patient. Prior infection with S-614D or S-614G strains efficiently prevented the replication of the P.1 variant in the lower respiratory tract of hamsters upon reinfection. In addition, passive transfer of neutralizing antibodies to hamsters infected with the P.1 variant or the S-614G strain led to reduced virus replication in the lower respiratory tract. However, the effect was less pronounced against the P.1 variant than the S-614G strain. These findings suggest that the P.1 variant may be somewhat antigenically different from the early and contemporary strains of SARS-CoV-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Virus Replication / SARS-CoV-2 / COVID-19 Type of study: Prognostic study Limits: Animals / Humans Country/Region as subject: South America / Brazil Language: English Year: 2021 Document Type: Article Affiliation country: Pnas.2106535118

Full text: Available Collection: International databases Database: MEDLINE Main subject: Virus Replication / SARS-CoV-2 / COVID-19 Type of study: Prognostic study Limits: Animals / Humans Country/Region as subject: South America / Brazil Language: English Year: 2021 Document Type: Article Affiliation country: Pnas.2106535118